首页> 外文期刊>Journal of toxicology and environmental health, Part A >Pediatric atomoxetine ingestions reported to Texas poison control centers, 2003-2005.
【24h】

Pediatric atomoxetine ingestions reported to Texas poison control centers, 2003-2005.

机译:向德克萨斯州毒物控制中心报告了小儿阿托西汀的摄入,2003-2005年。

获取原文
获取原文并翻译 | 示例
       

摘要

Limited information exists on potentially adverse consequences following pediatric atomoxetine ingestions reported to poison control centers. Using pediatric atomoxetine ingestions reported to Texas poison control centers during 2003-2005, the proportion of cases involving serious outcomes (medical outcomes classified as moderate effects, major effects, death, or judged as potentially toxic exposures) was determined for selected variables and evaluated for statistical significance by calculating the rate ratio (RR) and 95% confidence interval (CI). Of 501 cases identified, 31 (6%) involved serious outcomes. Higher serious outcome rates were found with a maximum dose of >2.8 mg/kg or >200 mg or >4 tablets. Serious outcome rates were also higher if the exposure involved intentional self-harm or the patient was already at or en route to a health care facility when the poison control center was contacted or referred to a health care facility by the poison control center. The severity of the outcome associated with pediatric atomoxetine ingestions was dependent upon the dose and the circumstances of the ingestion (whether intentional self-harm was involved). The management of patients with serious outcomes was more likely to involve health care facilities. This information is useful for creating triage guidelines for the management of pediatric atomoxetine ingestions.
机译:关于向儿童中毒控制中心报告的儿童吸入阿托西汀后可能产生的不良后果的信息有限。使用2003年至2005年间向德克萨斯州毒物控制中心报告的儿科阿托西汀摄入量,对选定变量确定了涉及严重结局(医学结局分类为中度影响,主要影响,死亡或判断为潜在毒性暴露)的病例比例,并评估了通过计算比率(RR)和95%置信区间(CI)获得统计显着性。在确定的501例病例中,有31例(6%)涉及严重后果。发现最大剂量> 2.8 mg / kg或> 200 mg或> 4片时,严重后果的发生率更高。如果接触涉及到故意的自我伤害,或者当毒物控制中心与毒物控制中心联系或转诊到医疗机构时,患者已经在或正在前往医疗机构时,严重的结局率也更高。与儿童吸入阿托西汀有关的结局严重程度取决于剂量和摄入情况(是否涉及故意的自我伤害)。具有严重后果的患者的管理更可能涉及医疗机构。该信息对于创建用于儿科阿托西汀摄入管理的分类指南非常有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号